BR112016012792A2 - Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras - Google Patents
Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladorasInfo
- Publication number
- BR112016012792A2 BR112016012792A2 BR112016012792A BR112016012792A BR112016012792A2 BR 112016012792 A2 BR112016012792 A2 BR 112016012792A2 BR 112016012792 A BR112016012792 A BR 112016012792A BR 112016012792 A BR112016012792 A BR 112016012792A BR 112016012792 A2 BR112016012792 A2 BR 112016012792A2
- Authority
- BR
- Brazil
- Prior art keywords
- biomarkers
- treatment
- methods
- predictor
- clinical sensitivity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913046P | 2013-12-06 | 2013-12-06 | |
| PCT/US2014/068767 WO2015085160A2 (en) | 2013-12-06 | 2014-12-05 | Methods for treating hematological cancers and the use of biomarkers as a predictor of clinical sensitivity to immunodulatory therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016012792A2 true BR112016012792A2 (pt) | 2017-08-08 |
Family
ID=53274284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016012792A BR112016012792A2 (pt) | 2013-12-06 | 2014-12-05 | Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20160312292A1 (https=) |
| EP (1) | EP3077547A4 (https=) |
| JP (1) | JP2017503481A (https=) |
| KR (1) | KR20160090390A (https=) |
| AU (1) | AU2014360316A1 (https=) |
| BR (1) | BR112016012792A2 (https=) |
| CA (1) | CA2932266A1 (https=) |
| EA (1) | EA201691143A1 (https=) |
| IL (1) | IL245936A0 (https=) |
| MX (1) | MX2016007179A (https=) |
| PH (1) | PH12016501023A1 (https=) |
| WO (1) | WO2015085160A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160282354A1 (en) | 2013-11-08 | 2016-09-29 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| IL278381B2 (en) | 2013-12-06 | 2024-08-01 | Celgene Corp | Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer |
| EP3207521B1 (en) * | 2014-10-17 | 2022-11-02 | Stichting Maastricht Radiation Oncology "Maastro Clinic" | Image analysis method supporting illness development prediction for a neoplasm in a human or animal body |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| US11459613B2 (en) | 2015-09-11 | 2022-10-04 | The Brigham And Women's Hospital, Inc. | Methods of characterizing resistance to modulators of Cereblon |
| CA2999179A1 (en) * | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| CA3010801A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| JP7357921B2 (ja) * | 2017-09-29 | 2023-10-10 | 国立大学法人九州大学 | びまん性大細胞型ｂ細胞リンパ腫患者における化学療法に対する治療効果を予測するための方法及びキット |
| CA3154890A1 (en) * | 2019-10-21 | 2021-04-29 | Maria Soraya Carrancio ANTON | Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dion |
| WO2024258819A1 (en) * | 2023-06-15 | 2024-12-19 | The Broad Institute, Inc. | Neoplastic cytotoxicity induced by glycosylation |
| FR3158743A1 (fr) * | 2024-01-30 | 2025-08-01 | Universite Grenoble Alpes | Biomarqueurs et outil pronostique pour les patients atteint de lymphomes b diffus a grandes cellules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2235213A2 (en) * | 2007-12-20 | 2010-10-06 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| TWI509247B (zh) * | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| CA2834535A1 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
-
2014
- 2014-12-05 KR KR1020167017539A patent/KR20160090390A/ko not_active Withdrawn
- 2014-12-05 EP EP14867978.0A patent/EP3077547A4/en not_active Withdrawn
- 2014-12-05 EA EA201691143A patent/EA201691143A1/ru unknown
- 2014-12-05 MX MX2016007179A patent/MX2016007179A/es unknown
- 2014-12-05 BR BR112016012792A patent/BR112016012792A2/pt not_active Application Discontinuation
- 2014-12-05 JP JP2016536527A patent/JP2017503481A/ja active Pending
- 2014-12-05 US US15/101,866 patent/US20160312292A1/en not_active Abandoned
- 2014-12-05 CA CA2932266A patent/CA2932266A1/en not_active Abandoned
- 2014-12-05 WO PCT/US2014/068767 patent/WO2015085160A2/en not_active Ceased
- 2014-12-05 AU AU2014360316A patent/AU2014360316A1/en not_active Abandoned
-
2016
- 2016-05-31 IL IL245936A patent/IL245936A0/en unknown
- 2016-05-31 PH PH12016501023A patent/PH12016501023A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PH12016501023A1 (en) | 2016-07-04 |
| IL245936A0 (en) | 2016-07-31 |
| WO2015085160A2 (en) | 2015-06-11 |
| EP3077547A2 (en) | 2016-10-12 |
| CA2932266A1 (en) | 2015-06-11 |
| EP3077547A4 (en) | 2017-11-08 |
| JP2017503481A (ja) | 2017-02-02 |
| EA201691143A1 (ru) | 2016-11-30 |
| AU2014360316A1 (en) | 2016-06-16 |
| WO2015085160A3 (en) | 2015-07-30 |
| MX2016007179A (es) | 2016-09-08 |
| US20160312292A1 (en) | 2016-10-27 |
| KR20160090390A (ko) | 2016-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016012792A2 (pt) | Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras | |
| CY1125398T1 (el) | Anti-vista αντισωματα και θραυσματα | |
| IL260774B (en) | Preparations containing 3cd19 x cd bispecific antibodies for the treatment of tumors of lymph node tissue and/or extra-lymph node lymphoma as a result of diffuse large b-cell lymphoma (dlbcl) | |
| BR112016018044A2 (pt) | teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer | |
| MX367042B (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer. | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| BR112015022934A8 (pt) | esteróides neuroativos, composições e usos destes | |
| BR112020002012A8 (pt) | Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 | |
| MX380555B (es) | Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores. | |
| BR112014005427A2 (pt) | método implantado por um dispositivo de computação | |
| GB2519906A (en) | Methods and systems for detecting biological components | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| AR080505A1 (es) | Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| EP4497824A3 (en) | Methods and materials for assessing loss of heterozygosity | |
| BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
| WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
| BR112016024143A2 (pt) | tratamento de câncer | |
| BR112017016808A2 (pt) | biomarcadores para câncer pancreático | |
| BR112017001586A2 (pt) | ?aparelho e método para gerar um sinal aprimorado com o uso de preenchimento por ruído independente?. | |
| EA201401201A1 (ru) | Способ | |
| EP3457138A3 (en) | Novel biomarkers for acute myeloid leukemia | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
| NZ629700A (en) | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy | |
| WO2014184684A3 (en) | Methods and biomarkers for detection of hematological cancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |